Sucampo Pharmaceuticals, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of ______________ Debt SecuritiesIndenture • June 9th, 2017 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2017 Company Industry JurisdictionIndenture, dated as of ________, among Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):
SUCAMPO PHARMACEUTICALS, INC. and ________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF _____________Common Stock Warrant Agreement • June 9th, 2017 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2017 Company Industry JurisdictionCommon Stock Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
SUCAMPO PHARMACEUTICALS, INC. and ________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ______________Warrant Agreement • June 9th, 2017 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2017 Company Industry JurisdictionDebt Securities Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
sucampo pharmaceuticals, INC. and ________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ___________Preferred Stock Warrant Agreement • June 9th, 2017 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 9th, 2017 Company Industry JurisdictionPreferred Stock Warrant Agreement (this “Agreement”), dated as of between Sucampo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).